BeiGene Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
Article By: ChinaBio® Today
Saturday, October 15, 2022 5:40 PM EDT
Deals, financings, trials and approvals on the China biotech/pharma market.
In this article: RHHBY, BGNE, CABA
Read
Top Biotech Bets From The Baker Brothers
Article By: MoneyShow.com
Wednesday, September 28, 2022 5:00 AM EDT
Baker Bros. Advisors is a private hedge fund based. Investors that are familiar with biotech companies are likely to find some hidden gems amongst their holdings.
In this article: ACAD, BMRN, BGNE, INCY
Read
Week In Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO In Guangzhou
Article By: ChinaBio® Today
Saturday, April 16, 2022 3:11 PM EDT
Deals, financings, trials and approvals in biotech in China this week.
In this article: BGNE, VTGN
Read
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
Article By: ChinaBio® Today
Saturday, May 22, 2021 2:05 PM EDT
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.
In this article: BGNE, BNR, MIST, LABP
Read
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
Article By: ChinaBio® Today
Saturday, April 10, 2021 12:55 PM EDT
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in China. 
In this article: SRNE, HCM, BGNE, IMAB
Read

Latest Tweets for $BGNE

No tweets yet!

PARTNER HEADLINES

$BGNE

The World Has Turned Sunny
Marcy Brown 11/10/2020 2:19:18 AM

I don't really understand why $BGNE was downrated. The news was positive.

1 to 1 of 1 comments